Background: β-Blockers have been found to reduce mortality and morbidity in postmyocardial infarction patients. However, it is not fully understood whether all β-blockers have similar favourable cardiovascular effects. The aim of this study was to compare the effects of carvedilol and atenolol on global and regional left ventricular ejection fraction (LVEF) and on predefined cardiovascular endpoints. Methods: In a single-centre, randomized, open, endpoint-blinded, parallel group study, 232 patients with acute myocardial infarction were randomized to treatment with carvedilol or atenolol. LVEF was measured by gated blood pool scintigraphy during the first week and after 12 months. The treatment was given orally within 24 h. The mean dose was 36.2 and 72.1 mg in the carvedilol and atenolol groups, respectively. Results: No significant difference was found between the two study groups in the mean global and regional LVEF. There tended to be fewer first serious cardiovascular events in the carvedilol compared with the atenolol group (RR = 0.83, 95% CI 0.56–1.23, p = 0.39). Cold hands and feet were observed less frequently in the carvedilol group (20 vs. 33%, p = 0.025). Conclusion: In patients following an acute myocardial infarction, no difference in either global or regional LVEF was observed between baseline and 12 months when treatment with carvedilol was compared with atenolol.

Keywords:
Myocardial infarction, Atenolol, Carvedilol, Serious cardiovascular events, Left ventricular ejection fraction, Remodelling, Adverse events
1.
Norwegian Multicenter Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801–807.
2.
β-Blocker Heart Attack Trial Research Group: A randomized trial of propanolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 1982;247:1707–1714.
3.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.
4.
Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E, Schusterman N: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.
5.
CIBIS-II Investigators: The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999;353:9–13.
6.
The MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–2007.
7.
The Australia/New Zealand Carvedilol Study Heart Failure Research Collaborative Group: Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375–380.
8.
The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385–1390.
9.
Ruffolo RR Jr, Bril A, Feuerstein GZ: Cardioprotective potential of carvedilol. Cardiology 1993;82(suppl 3):24–28.
10.
Feuerstein GZ, Hamburger SA, Smith EF 3rd, Bril A, Ruffolo RR Jr: Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19(suppl 1):S138–S141.
11.
Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nicholas AJ: The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38(suppl 2):S82–S88.
12.
Nichols AJ, Gellai M, Ruffolo RR Jr: Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol 1991;5:25–38.
13.
Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr: In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol. Pharmacology 1989;39:327–336.
14.
Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92–98.
15.
Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr: Myocardial protection by novel vasodilating beta-blocker, carvedilol: Potential relevance of anti-oxidant activity. J Hypertens 1993;11(suppl 4):S41–S48.
16.
Yue TL, McKenna PJ, Lysko PG, Ruffolo RR Jr, Feuerstein GZ: Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992;97:209–216.
17.
Sung CP, Arleth AJ, Ohlstein EH: Carvedilol inhibits vascular smoth muscle cell proliferation. J Cardiovasc Pharmacol 1993;21:221–227.
18.
Albrightson CR, Zabko-Potapovich B, Brooks DP: Effect of carvedilol on mitogen-stimulated mesangial cell proliferation. Pharmacol Commun 1992;1:267–272.
19.
Jonsson G, Fossum E, Kjeldsen SE, Høieggen A, Os I, Eide I, Westheim A: Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press 2002;11:377–384.
20.
Bernstein R, Müller C, Midtbø K, Haug E, Nakken KF, Hertzenberg G, Kjørstad KF: Cardiac left ventricular function before and during early thyroxine treatment in severe hypothyroidism. J Int Med 1991;230:493–500.
21.
Folland ED, Hamilton GW, Larson SM, Kennedy JW, Williams DL, Ritchie JL: The radionuclide ejection fraction: A comparison of three radionuclide techniques with contrast angiography. J Nucl Med 1977;18:1159–1166.
22.
Vickers AJ, Altman DG: Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123–1124.
23.
Kleinbaum DG, Kupper LL, Muller KE: Applied Regression Analysis and Other Multivariate Methods. Boston, PWS-Kent Publishing Company, 1988.
24.
Lee ET: Statistical Methods for Survival Data Analysis. Belmont, Lifetime Learning Publications, 1980.
25.
Basu S, Senior R, Raul U, van der Does R, Bruckner T, Lahiri A: Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96:183–191.
26.
Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Sherag A, Lutiger B, Ryden L: The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57–66.
27.
Bristow MR: Mechanisms of action of beta-blocking agents in heart failure. Am J Cardiol 1997;80:26L–40L.
28.
Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze G: Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study. J Hypertens 1996;14:489–494.
29.
Ruffolo RR Jr, Sauermelch CF, Willette RN: Hemodynamic differences between carvedilol and labetolol in cutaneous circulation. Eur J Clin Pharmacol 1990;38:S112–S114.
30.
Cournot A, Lim C, Duchier J, Safar M: Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects. J Cardiovasc Pharmacol 1992;19 (suppl 1):S35–S39.
31.
Klemsdal TO, Mundal H, Gjesdal K: Effects of carvedilol and atenolol on arterial pulse curves (pletysmography) and finger temperature after hand cooling. Eur J Clin Pharmacol 1996;50:483–489.
32.
Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F: Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarcto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897–1903.
33.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821–828.
34.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309–1321.
35.
Chan AW, Quinn MJ, Bhatt DL, Chew DP, Moliterno DJ, Topol EJ, Ellis SG: Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:669–675.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.